When: Daily close above 10 EMA ($660.86) with recovering MACD histogram

Then: Re-enter per sizing rules

Hold existing position without adding new risk until Q3 confirms or denies the setup; do not press into full conviction ahead of binary catalyst

• Forward EPS target of 27.58 requires unprecedented 47 percent sequential acceleration with no historical precedent
• Revenue acceleration to 11.99 billion (up 10.5 percent YoY) does not guarantee bottom-line acceleration due to goodwill-heavy balance sheet and 8.87 billion dollar acquisition integration risk
• Technical setup shows distribution cluster: lower highs in momentum while price made higher highs, histogram from negative 1.28 to negative 3.56, ATR expansion of 27 percent, bearish outside day closing at intraday low on above-average volume
• 50 SMA sits 4.4 percent below current price; 200 SMA is 19.9 percent below current price
• 624 support level is not a hard floor and could be tested severely if long-end yields spike into Q3 print
• 96 percent no-cuts pricing is the status quo bear case; higher for longer compresses 23.6 times forward multiple
• Midterm drug pricing risks including NIH funding pressure, academic research budget cuts, and IRA expansion to diagnostics pricing directly impact TMO end markets
• Earnings catalyst presents negative expected value: 5 to 7 percent upside on beat-and-raise versus 5 to 12 percent downside on miss
• Options market pricing 4 to 6 percent implied moves, but realized moves on disappointment historically exceed implied
• 50 percent sizing rule is recommended as prudent risk management to survive if bear case resolves

→ vs aggressive: Revenue acceleration (10.5 percent YoY) does not bridge the gap to 47 percent sequential EPS acceleration required by the 27.58 target; conflating top-line momentum with bottom-line acceleration is a category error

→ vs aggressive: MACD divergence resolution to upside is survivorship bias; the bearish resolutions are catastrophic, and current setup is a stacked configuration of multiple bearish signals

→ vs aggressive: Absence of bearish news does not equal bullish sentiment; quiet tape often equals distribution at higher levels by smart money, not accumulation

→ vs aggressive: 96 percent no-cuts pricing is not upside optionality but the central scenario that directly compresses duration-sensitive multiples at 23.6 times forward earnings

→ vs aggressive: Earnings asymmetry math inverts the bullish argument: downside of 5 to 12 percent exceeds upside of 5 to 7 percent, making it a negative expected value setup

→ vs aggressive: Historical EPS beats are a self-selecting sample; misses are also historical, and risk of disappointment after run from 540s to 680s is asymmetric to downside

→ vs aggressive: Aggressive case assumes everything goes right; conservative case ensures survival if it does not; pressing into full conviction at 23 times forward with binary catalyst in three weeks is not commercially defensible

Maintain HOLD on existing position; use 50% sizing for incremental entries, targeting 50 SMA test around $624 or a breakout above $660 to convert to full position; stop at $605 (2.7% below current, below lower Bollinger band at $618); monitor 10-year yield alongside stock.

• Revenue acceleration to $11.99B is real, but the 47% sequential EPS acceleration requirement is the central valuation question
• Forward EPS at 23.6x; if EPS comes down to $25, fair value drops to ~$590 against current $652
• Options-implied move of 4-6% is more accurate than the conservative's 5-12% downside framing or aggressive's 5-7% upside framing
• Price holding 4.4% above 50 SMA and ~20% above 200 SMA; textbook distribution would break the 50 SMA, which hasn't happened
• Polymarket shows 6% recession probability (down 2pp week-over-week), consistent with soft landing and disinflation
• Beta of 0.88 means stock should outperform on risk-off days from hawkish Fed; contradicting the conservative's hawkish Fed concern
• Stop at $605 sits ~2.7% below current and below lower Bollinger band at $618, appropriate for trend invalidation
• 10-year yield breakout is an underweighted risk that could test the stop regardless of TMO's earnings

→ vs aggressive: Narrative is overriding arithmetic—10% revenue growth and 1.8% share count reduction cannot bridge a 47% EPS acceleration gap; that's a category error

→ vs aggressive: MACD divergence needs Q3 earnings as a catalyst to resolve; it doesn't pre-resolve bullishly, it sits until the print is binary

→ vs aggressive: "No retail chatter equals institutional accumulation" is a logical leap; absence of evidence is not evidence of accumulation

→ vs aggressive: 200 SMA being 19.9% below isn't margin of safety—it's evidence the stock has already done the work

→ vs conservative: Overweighting macro tail while underweighting franchise quality; Beta of 0.88 means outperforming on hawkish Fed days, which is the scenario being worried about—an internal contradiction

→ vs conservative: MACD lower highs, ATR expansion, and weak close are caution flags but not confirmation; price is still well above both the 50 and 200 SMA; textbook distributions break the 50 SMA, which hasn't occurred

→ vs conservative: Collapsing caution into confirmation; 5-12% downside requires multi-trigger tail scenario, more pessimistic than 4-6% options-implied move

→ vs conservative: 6% recession probability (down 2pp week-over-week) supports recurring revenue and consumables franchise; soft landing thesis is strengthening